Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: a Report from the Children's Oncology Group

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2010 Feb 4

PMID 20124188

Citations 46

Authors

Elai Davicioni

James R Anderson

Jonathan D Buckley

William H Meyer

Timothy J Triche

Affiliations

Soon will be listed here.

Abstract

Purpose: We investigated whether tumors from diagnostic biopsies of primary rhabdomyosarcoma (RMS) contain relevant prognostic information in the form of gene expression signatures that can be used to model and predict outcome of patients.

Patients And Methods: A 22,000-probe set microarray was used to evaluate 120 RMS specimens and correlate gene expression patterns to survival. Multivariate gene expression models or metagenes were developed using cross-validated Cox regression proportional hazards modeling and were evaluated using Kaplan-Meier analysis.

Results: A 34-metagene, based on expression patterns of 34 genes, was highly predictive of outcome. It was not highly correlated with individual clinical risk factors such as patient age, stage, tumor size, or histology. However, it was correlated with a risk classification used by the Children's Oncology Group and the biologic subsets of alveolar histology tumors.

Conclusion: These data support further evaluation of RMS metagenes to discriminate patients with good prognosis from those with poor prognosis, with the potential to direct risk-adapted therapy.

Citing Articles

Prognostic factors in patients with localized and metastatic alveolar rhabdomyosarcoma. A report from two studies and two registries of the Cooperative Weichteilsarkom Studiengruppe CWS.

Koscielniak E, Stegmaier S, Ljungman G, Kazanowska B, Niggli F, Ladenstein R Cancer Med. 2025; 14(1):e70215.

PMID: 39781573 PMC: 11712121. DOI: 10.1002/cam4.70215.

Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).

Chisholm J, Mandeville H, Adams M, Minard-Collin V, Rogers T, Kelsey A Cancers (Basel). 2024; 16(5).

PMID: 38473359 PMC: 10931395. DOI: 10.3390/cancers16050998.

Identify potential driver genes for PAX-FOXO1 fusion-negative rhabdomyosarcoma through frequent gene co-expression network mining.

Zhan X, Liu Y, Jannu A, Huang S, Ye B, Wei W Front Oncol. 2023; 13:1080989.

PMID: 36793601 PMC: 9924292. DOI: 10.3389/fonc.2023.1080989.

Autoantibody profiling of alveolar rhabdomyosarcoma patients unveils tumor-associated antigens with diagnostic and prognostic significance.

Poli E, Cattelan M, Zanetti I, Scagnellato A, Giordano G, Zin A Oncoimmunology. 2021; 10(1):1954765.

PMID: 34367733 PMC: 8312597. DOI: 10.1080/2162402X.2021.1954765.

Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Heske C, Chi Y, Venkatramani R, Li M, Arnold M, Dasgupta R Cancer. 2020; 127(6):946-956.

PMID: 33216382 PMC: 8601034. DOI: 10.1002/cncr.33334.

References

Simon R, Radmacher M, Dobbin K, McShane L . Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 2003; 95(1):14-8. DOI: 10.1093/jnci/95.1.14. View

Meyer W, Spunt S . Soft tissue sarcomas of childhood. Cancer Treat Rev. 2004; 30(3):269-80. DOI: 10.1016/j.ctrv.2003.11.001. View

Ramaswamy S, Ross K, Lander E, Golub T . A molecular signature of metastasis in primary solid tumors. Nat Genet. 2002; 33(1):49-54. DOI: 10.1038/ng1060. View

Pappo A, ANDERSON J, Crist W, Wharam M, Breitfeld P, Hawkins D . Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999; 17(11):3487-93. DOI: 10.1200/JCO.1999.17.11.3487. View

Du S, Lawrence E, Strzelecki D, Rajput P, Xia S, Gottesman D . Co-expression of alternatively spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct DNA binding and transactivation properties in rhabdomyosarcoma. Int J Cancer. 2005; 115(1):85-92. DOI: 10.1002/ijc.20844. View

Simon R . Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol. 2005; 23(29):7332-41. DOI: 10.1200/JCO.2005.02.8712. View

Breneman J, Lyden E, Pappo A, Link M, Anderson J, Parham D . Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2002; 21(1):78-84. DOI: 10.1200/JCO.2003.06.129. View

Pursglove S, Mackay J . CSL: a notch above the rest. Int J Biochem Cell Biol. 2005; 37(12):2472-7. DOI: 10.1016/j.biocel.2005.06.013. View

Weigelt B, Hu Z, He X, Livasy C, Carey L, Ewend M . Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005; 65(20):9155-8. DOI: 10.1158/0008-5472.CAN-05-2553. View

10.

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

11.

McDowell H . Update on childhood rhabdomyosarcoma. Arch Dis Child. 2003; 88(4):354-7. PMC: 1719509. DOI: 10.1136/adc.88.4.354. View

12.

Nagle J, Ma Z, Byrne M, White M, Shaw L . Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol. 2004; 24(22):9726-35. PMC: 525494. DOI: 10.1128/MCB.24.22.9726-9735.2004. View

13.

RANEY R, ANDERSON J, Barr F, Donaldson S, Pappo A, Qualman S . Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 2002; 23(4):215-20. DOI: 10.1097/00043426-200105000-00008. View

14.

Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J . Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol. 2006; 24(5):816-22. DOI: 10.1200/JCO.2005.03.4934. View

15.

Sakamuro D, Prendergast G . New Myc-interacting proteins: a second Myc network emerges. Oncogene. 1999; 18(19):2942-54. DOI: 10.1038/sj.onc.1202725. View

16.

Thies A, Schachner M, Moll I, Berger J, Schulze H, Brunner G . Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer. 2002; 38(13):1708-16. DOI: 10.1016/s0959-8049(02)00105-3. View

17.

Crist W, ANDERSON J, Meza J, Fryer C, RANEY R, RUYMANN F . Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001; 19(12):3091-102. DOI: 10.1200/JCO.2001.19.12.3091. View

18.

Wechsler-Reya R, Elliott K, Prendergast G . A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Mol Cell Biol. 1998; 18(1):566-75. PMC: 121524. DOI: 10.1128/MCB.18.1.566. View

19.

Meza J, Anderson J, Pappo A, Meyer W . Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol. 2006; 24(24):3844-51. DOI: 10.1200/JCO.2005.05.3801. View

20.

Stevens M . Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol. 2005; 6(2):77-84. DOI: 10.1016/S1470-2045(05)01733-X. View